Title: Observation on three-year follow-up curative effect of entecavir combined with lamivudine on decompensated hepatitis B cirrhosis
Abstract: Objective
To observe the long-term curative effect of entecavir combined with lamivudine on decompensated hepatitis B cirrhosis.
Methods
The patients with decompensated hepatitis B cirrhosis were selected as study subjects, and were divided into the observation group (entecavir and lamivudine combined therapy) and the control group (lamivudine alone). The changes of liver function indexes, hepatitis B virus gene (HBV-DNA) level, liver reserve function quantization evaluation grading standard (Child-Pugh score) and model for end-stage liver disease (MELD) score before and after follow-up were observed.
Results
With 12, 24 and 36 months of follow-up, the levels of alanine aminotransferase (ALT), the decline of serum HBV-DNA level, the Child-Pugh score and MELD score in the observation group were significantly different with those in the control group (all P<0.05).
Conclusions
The curative effect of entecavir combined with lamivudine is significant. The liver function in patients is significantly improved, and hepatitis B virus is well controlled. The drug resistance and safety are good.
Key words:
Entecavir; Lamivudine; Hepatitis B; Liver cirrhosis; Follow-up
Publication Year: 2016
Publication Date: 2016-10-10
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot